Switch theme
Sign up to access all valuation multiples
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2024, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 36% of Terumo’s revenue.
1921
26.5K+
LTM Revenue $6.8B
LTM EBITDA $1.7B
$26.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Terumo has a last 12-month revenue of $6.8B and a last 12-month EBITDA of $1.7B.
In the most recent fiscal year, Terumo achieved revenue of $6.1B and an EBITDA of $1.5B.
Terumo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Terumo valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.5B | $6.1B | XXX | XXX | XXX |
| Gross Profit | $2.5B | $2.8B | XXX | XXX | XXX |
| Gross Margin | 45% | 45% | XXX | XXX | XXX |
| EBITDA | $1.3B | $1.5B | XXX | XXX | XXX |
| EBITDA Margin | 23% | 24% | XXX | XXX | XXX |
| Net Profit | $590M | $594M | XXX | XXX | XXX |
| Net Margin | 11% | 10% | XXX | XXX | XXX |
| Net Debt | $138M | $297M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Terumo's stock price is JPY 2676 (or $18).
Terumo has current market cap of JPY 3.95T (or $26.2B), and EV of JPY 3.92T (or $26.1B).
See Terumo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.1B | $26.2B | XXX | XXX | XXX | XXX | $0.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Terumo has market cap of $26.2B and EV of $26.1B.
Terumo's trades at 3.8x LTM EV/Revenue multiple, and 15.3x LTM EBITDA.
Analysts estimate Terumo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Terumo and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $26.1B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 16.0x | XXX | XXX | XXX |
| P/E | 31.9x | XXX | XXX | XXX |
| P/E/Growth | 2.0x | XXX | XXX | XXX |
| EV/FCF | 49.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTerumo's NTM/LTM revenue growth is 7%
Terumo's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Terumo's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Terumo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Terumo and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 32% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 37% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius Medical Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Terumo acquired XXX companies to date.
Last acquisition by Terumo was XXXXXXXX, XXXXX XXXXX XXXXXX . Terumo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Terumo founded? | Terumo was founded in 1921. |
| Where is Terumo headquartered? | Terumo is headquartered in Japan. |
| How many employees does Terumo have? | As of today, Terumo has 26.5K+ employees. |
| Who is the CEO of Terumo? | Terumo's CEO is Mr. Hikaru Samejima. |
| Is Terumo publicy listed? | Yes, Terumo is a public company listed on TKS. |
| What is the stock symbol of Terumo? | Terumo trades under 4543 ticker. |
| When did Terumo go public? | Terumo went public in 1982. |
| Who are competitors of Terumo? | Similar companies to Terumo include e.g. Ansell, Polymed, Schott Pharma, Fresenius Medical Care. |
| What is the current market cap of Terumo? | Terumo's current market cap is $26.2B |
| What is the current revenue of Terumo? | Terumo's last 12-month revenue is $6.8B. |
| What is the current EBITDA of Terumo? | Terumo's last 12-month EBITDA is $1.7B. |
| What is the current EV/Revenue multiple of Terumo? | Current revenue multiple of Terumo is 3.8x. |
| What is the current EV/EBITDA multiple of Terumo? | Current EBITDA multiple of Terumo is 15.3x. |
| What is the current revenue growth of Terumo? | Terumo revenue growth between 2023 and 2024 was 12%. |
| Is Terumo profitable? | Yes, Terumo is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
